[CAS NO. 426219-18-3]  TAK-700 (Orteronel)

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [426219-18-3]

Store
Catalog
AS952875
Brand
Arctom Scientific
CAS
426219-18-3

DESCRIPTION [426219-18-3]

Overview

MDLMFCD17677399
Molecular Weight307.35
Molecular FormulaC18H17N3O2
SMILESO=C(NC)C1=CC=C2C=C(C3(O)CCN4C=NC=C43)C=CC2=C1

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM3.2536 mL16.2681 mL32.5362 mL
5 mM0.6507 mL3.2536 mL6.5072 mL
10 mM0.3254 mL1.6268 mL3.2536 mL
50 mM0.0651 mL0.3254 mL0.6507 mL

Description

TAK-700 (Orteronel) is a potent and highly selective human inhibitor with of 38 nM, exhibits >1000-fold selectivity over other CYPs (e.g. 11-hydroxylase and CYP3A4). TAK-700 (Orteronel) is an biosynthesis inhibitor. Phase 3.

Targets

17,20-lyase (Human) [1]17,20-lyase (Rat) [1]
38 nM54 nM

In vitro

In vitro, TAK-700 shows the potent inhibitory activity against rat and human steroid 17,20-lyase with IC50 of 54 nM and 38 nM, respectively. While other CYP isoforms including 11-hydroxylase and CYP3A4 are not significantly affected by TAK-700. In microsomes expressing human CYP isoforms, TAK-700 exhibit greater inhibitory effects on 17,20-lyase with IC50 of 19 nM compared to the other CYP isoforms. TAK-700 shows the inhibitory activity against monkey 17,20-lyase and 17-hydroxylase with IC50 of 27 nM and 38 nM, respectively. In monkey adrenal cells, TAK-700 inhibits the ACTH stimulated production of DHEA and androstenedione with IC50 of 110 nM and 130 nM, respectively. Moreover, TAK-700 also potently inhibits DHEA production in human adrenocortical tumor line H295R cells with IC50 of 37 nM.

In vivo

In cynomolgus monkeys, oral treatment of TAK-700 at a dose of 1 mg/kg markedly reduces serum testosterone and dehydroepiandrosterone (DHEA) levels. Oral treatment of TAK-700 at a dose of 1 mg/kg results in favorable pharmacokinetic parameters with T, C, t and AUC of 1.7 hours, 0.147 μg/mL, 3.8 hours and 0.727 μg h/mL, respectively.